Found 1 Presentation For Request "1124P"
1124P - Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
- Antonio Passaro (Milan, Italy)
Abstract
Background
The selective RET-inhibitor pralsetinib has shown therapeutic activity in early clinical trials in patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (
Methods
A retrospective efficacy and safety analysis was performed on data from patients with RET fusion positive NSCLC who were enrolled in the pralsetinib Italian expanded access program (EAP) between July 2019 and October 2021.
Results
Overall, 60 patients with
Conclusions
In the real-world setting, pralsetinib confirmed durable systemic activity and intracranial response in RET fusion-positive NSCLC. Toxicity profile was consistent with previous reports.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Passaro: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, Janssen, Takeda, Boehringer Ingelheim, Mundipharma, Eli Lilly; Non-Financial Interests, Other, Scientific Committee for Lung Cancer Guideline: AIOM. All other authors have declared no conflicts of interest.